Clinical Trial Update: Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]

View source ↗

Summary

A Phase 1 trial update evaluating the combination of nivolumab and ipilimumab after donor stem cell transplantation in patients with high-risk refractory or rel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED